Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Research & Development data on file, last reported at $69.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 100.88% year-over-year to $69.4 million; the trailing twelve-month figure through Mar 2026 stood at $183.6 million (up 19.76% YoY), and the FY2025 full-year result was $119.5 million, up 7.75% from the prior year.
• Research & Development improved to $69.4 million in Q1 2026, from $29.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $69.4 million in Q1 2026 to a low of $5.5 million in Q4 2023.
• A 5-year average of $29.8 million and a median of $27.2 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development tumbled 73.69% in 2023 and jumped 397.75% in 2024, its largest moves.
• Tracing HRMY's Research & Development over 5 years: stood at $21.1 million in 2022, then slumped by 73.69% to $5.5 million in 2023, then jumped by 397.75% to $27.6 million in 2024, then rose by 5.72% to $29.2 million in 2025, then soared by 137.78% to $69.4 million in 2026.
• Business Quant data shows HRMY's Research & Development at $69.4 million in Q1 2026, $29.2 million in Q4 2025, and $55.0 million in Q3 2025.